Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Richard Daniell is EVP, Europe Commercial at Teva Pharmaceutical Industries. OQRO lists 16 transactions filed with the SEC under this name, the latest on Nov 12, 2026, each linked to the official Form 4.
EVP, Europe Commercial
Disclosures on record
16
Companies involved
1
Teva Pharmaceutical IndustriesTEVA
16 disclosures · Mar 2025 – Nov 2026 · 12 sold
Nov 9, 2026Sold~$1.07Mdisclosed Nov 12
DetailsOfficial recordNov 11, 2026Sold~$856Kdisclosed Nov 12
DetailsOfficial recordNov 9, 202625Kdisclosed Nov 12
DetailsOfficial recordNov 11, 202620Kdisclosed Nov 12
DetailsOfficial recordNov 9, 202625Kdisclosed Nov 12
DetailsOfficial recordNov 11, 202620Kdisclosed Nov 12
DetailsOfficial recordMar 5, 2025Sold~$769Kdisclosed Mar 7
DetailsOfficial recordMar 5, 2025Sold~$359Kdisclosed Mar 7
DetailsOfficial recordMar 4, 2025Sold~$887Kdisclosed Mar 6
DetailsOfficial recordMar 5, 2025Sold~$478Kdisclosed Mar 6
DetailsOfficial recordMar 4, 2025Sold~$344Kdisclosed Mar 6
DetailsOfficial recordMar 4, 2025Sold~$210Kdisclosed Mar 6
DetailsOfficial recordMar 5, 2025Sold~$185Kdisclosed Mar 6
DetailsOfficial recordMar 5, 2025Sold~$113Kdisclosed Mar 6
DetailsOfficial recordMar 3, 2025Sold~$798Kdisclosed Mar 5
DetailsOfficial recordMar 4, 2025Sold~$201Kdisclosed Mar 5
DetailsOfficial recordAs of the latest filing on , Richard Daniell reported holding 55,755 shares of Teva Pharmaceutical Industries (TEVA), worth about $2.48M at the last close of $45 (Nov 13, 2026). In the last 12 months, Richard Daniell sold $1.93M in 2 sales.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Teva Pharmaceutical Industries TEVA | 55,755 | 56K direct | $45 | $2.48M | Nov 11, 2026 |
Is this Richard Daniell’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Richard Daniell has no open-market purchase on record since 2018. Sales in each of the last 9 years.
Richard Daniell reported 0 open-market purchases and 46 sales since 2018; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $1.93M2×2 trades |
| 2025 | — | $4.35M10×10 trades |
| 2024 | — | $3.92M6×6 trades |
| 2023 | — | $1.13M4×4 trades |
| 2022 | — | $725K5×5 trades |
| 2021 | — | $1.18M5×5 trades |
| 2020 | — | $95K4×4 trades |
| 2019 | — | $80K5×5 trades |
| 2018 | — | $132K5×5 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 11, 2026, Richard Daniell reported holding 55,755 shares of Teva Pharmaceutical Industries (TEVA). At the last close of $45 on Nov 13, 2026, that is about $2.48M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Richard Daniell reported 2 open-market sales worth $1.93M, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Richard Daniell has no open-market purchase on record since 2018. Sales in each of the last 9 years.
In SEC filings since 2018: no open-market purchase is on record; the latest open-market sale is from 2026.
Teva Pharmaceutical Industries (TEVA), from 2018 to 2026: 0 purchases and 46 sales.
Richard Daniell reported 0 open-market purchases and 46 sales here, 2018 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
